<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1340">
  <stage>Registered</stage>
  <submitdate>25/11/2004</submitdate>
  <approvaldate>25/11/2004</approvaldate>
  <actrnumber>ACTRN12606000347561</actrnumber>
  <trial_identification>
    <studytitle>Multicenter Selective Lymphadenectomy Trial II (MSLT-II)</studytitle>
    <scientifictitle>A Phase III Multicenter Randomized Trial of Sentinel Lymphadenectomy followed by Serial Nodal Ultrasound versus Sentinel Lymphadenectomy followed by Complete Lymphadenectomy in Cutaneous Melanoma Patients with Molecular or Histopathological Evidence of Metastases in the Sentinel Node to Improve Melanoma Specific Survival.</scientifictitle>
    <utrn />
    <trialacronym>MLST II</trialacronym>
    <secondaryid>National Clinical Trials Registry: NCTR563</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Melanoma</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Malignant melanoma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Group 1: Complete lymph node dissection + ten years of follow up
Group 2: Observation with serial nodal ultrasound for first five years of ten years of  follow up</interventions>
    <comparator>Follow up with nodal ultrasound</comparator>
    <control>Active</control>
    <interventioncode>Treatment: surgery</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary endpoint is melanoma-specific survival.  This is defined as the time between the date of a subjects randomization (or date of complete lymph node dissection (CLND) for those randomized to the complete lymph node dissection arm) and the date of a subjects death due to melanoma.</outcome>
      <timepoint>All subjects are followed until death, or at least 10 years.  Follow up intervals are every four months for the first 2 years, every six months during years 3-5, and annually during years 6-10.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Disease free survival and time to recurrence.</outcome>
      <timepoint>Disease-free survival is defined as the time between the date of a subjects randomization (or date of CLND for those randomized to the CLND arm) and the date of a subjects diagnosis of first recurrence after randomization.  Recurrence is defined as the diagnosis of new sites of melanoma. The time to recurrence is the date at which recurrence is documented.  Only the date on which a recurrence was confirmed will be used as a recurrence date. Every recurrence will be sub-classified according to size and location.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Subjects must meet all of the following criteria to be eligible to randomize in this trial.1) Ability to provide informed consent. 2) Have a primary melanoma that is cutaneous (including head, neck, trunk, extremity, scalp, palm, sole, subungual skin tissues). 3) Have clear margins following wide local excision. 4) ECOG performance status 0-1. 5) Life expectancy of at least 10 years from the time of diagnosis, not considering the melanoma in question, as determined by the PI. 6) Willing to return to the MSLT-II center for follow up examinations and procedures as outlined in the protocol. 7) Randomization and/or complete lymph node dissection (as appropriate to randomization arm) must be completed no more than 120 days following the diagnostic biopsy of the primary melanoma. 8) Have a melanoma-related tumor-positive SN, determined by either of the following methods:a. Diagnosis of tumor-positive SN by MSLT-II center institutional pathologist by either H&amp;E or IHC (using S-100, Mart-1, and HMB-45).b. Diagnosis of tumor-positive SN by RT-PCR analysis performed at JWCI, provided the primary melanoma fits into one of the following categories:o Breslow thickness of 1.20 mm or greater and Clark Level IIIo Clark Level IV or V, regardless of Breslow thicknesso Ulceration, regardless of Breslow thickness or Clark level. 9)   Subjects must be male or female. </inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Subjects cannot meet any of the following criteria in order to be eligible to randomize in this trial.1) History of previous or concurrent (i.e., second primary) invasive melanoma.2) Primary melanoma of the eye, ears, mucous membranes or internal viscera.3) Physical, clinical, radiographic or pathologic evidence of satellite, in-transit, regional, or distant metastatic disease.4) Any additional solid tumor or hematologic malignancy during the past 5 years except T1 skin lesions of squamous cell carcinoma, basal cell carcinoma, or uterine cervical cancer.5) Skin grafts, tissue transfers or flaps that have the potential to alter the lymphatic drainage pattern from the primary melanoma to a LN basin.6) Allergy to vital blue dye or any radiocolloid.7) Inability to localize 1-2 SN drainage basins via LM (e.g., no basins found, more than 2 basins found, proximity of the primary melanoma to the regional draining basin, etc.)8) CLNDs or SLs (before evaluation of the current melanoma) that may have altered the lymphatic drainage pattern from the primary cutaneous melanoma to a potential LN basin.9) Organic brain syndrome or significant impairment of basal cognitive function or any psychiatric disorder that might preclude participation in the full protocol, or be exacerbated by therapy (e.g., severe depression).10) Melanoma-related operative procedures not corresponding to criteria described in the protocol.11) Primary or secondary immune deficiencies or known significant autoimmune disease.12) History of organ transplantation.13) Oral or parenteral immunosuppressive agents (not topical or inhaled steroids) at any time during study participation or within 6 months prior to enrollment.14) Pregnant or lactating women.15) Participation in concurrent experimental protocols or alternative therapies that might confound the analysis of this trial.  Adjuvant therapy protocols after recurrence are acceptable.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation is not concealed</concealment>
    <sequence>Random permuted variable size block design</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Bio-equivalence</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>30/09/2004</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>1925</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,VIC,QLD</recruitmentstate>
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Charities/Societies/Foundations</primarysponsortype>
    <primarysponsorname>John Wayne Cancer Institute</primarysponsorname>
    <primarysponsoraddress>2200 Santa Monica Blvd.
Santa Monica, CA 90404</primarysponsoraddress>
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Cancer Institute (NCI) grant  PO1 CA29605-12</fundingname>
      <fundingaddress>Bethesda, MD USA</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study is being conducted to prove/disprove the hypothesis that Sentinel Lymphadenectomy plus 5 years of serial nodal ultrasound is as effective as Sentinel Lymphadenectomy plus Complete Lymphadenectomy in prolonging disease free survival in patients with metastasis to the sentinel node.  This trial is unblinded.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>City Hospital of Nurnberg</ethicname>
      <ethicaddress />
      <ethicapprovaldate>6/09/2005</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Germany</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Dallas Surgical Group</ethicname>
      <ethicaddress />
      <ethicapprovaldate>20/04/2006</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>United States of America</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Greenville Hospital System Cancer Center</ethicname>
      <ethicaddress />
      <ethicapprovaldate>16/05/2006</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>United States of America</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>H.Lee Moffitt Cancer Center</ethicname>
      <ethicaddress />
      <ethicapprovaldate>17/01/2006</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>United States of America</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Hatton Institute of Research</ethicname>
      <ethicaddress />
      <ethicapprovaldate>26/05/2006</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>United States of America</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Helsinki University Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>3/01/2006</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Finland</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Huntsman Cancer Institute</ethicname>
      <ethicaddress />
      <ethicapprovaldate>19/07/2006</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>United States of America</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>IHC Cancer Services - LDS Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>27/10/2005</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>United States of America</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Istituto Europeo di Oncologia</ethicname>
      <ethicaddress />
      <ethicapprovaldate>7/07/2005</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Italy</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Istituto Nazionale Tumori Napoli</ethicname>
      <ethicaddress />
      <ethicapprovaldate>27/10/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Italy</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>John Wayne Cancer Institute</ethicname>
      <ethicaddress />
      <ethicapprovaldate>7/09/2004</ethicapprovaldate>
      <hrec>MORD-LM/SL-CLND-1102</hrec>
      <ethicsubmitdate />
      <ethiccountry>United States of America</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Lakeland Regional Cancer Center</ethicname>
      <ethicaddress />
      <ethicapprovaldate>16/09/2005</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>United States of America</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Main Line Surgeons</ethicname>
      <ethicaddress />
      <ethicapprovaldate>24/04/2006</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>United States of America</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Memorial Hospital - Colorado Springs</ethicname>
      <ethicaddress />
      <ethicapprovaldate>21/03/2006</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>United States of America</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Millard Fillmore Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>22/09/2005</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>United States of America</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Newcastle Melanoma Unit</ethicname>
      <ethicaddress />
      <ethicapprovaldate>4/05/2005</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>OSF Saint Francis Medical Center</ethicname>
      <ethicaddress />
      <ethicapprovaldate>13/09/2005</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>United States of America</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Padua University - Clinica Chirurgica II</ethicname>
      <ethicaddress />
      <ethicapprovaldate>10/10/2005</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Italy</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Princess Alexandra Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>27/10/2005</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Roswell Park Cancer Institute</ethicname>
      <ethicaddress />
      <ethicapprovaldate>15/03/2006</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>United States of America</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Sharp Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>14/12/2005</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>United States of America</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St. Louis University</ethicname>
      <ethicaddress />
      <ethicapprovaldate>20/09/2005</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>United States of America</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>St. Luke's Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>3/04/2006</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>United States of America</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Swedish Melanoma Study Group</ethicname>
      <ethicaddress />
      <ethicapprovaldate>1/12/2005</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Sweden</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Sydney Melanoma Unit</ethicname>
      <ethicaddress />
      <ethicapprovaldate>7/10/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Tel-Aviv Sourasky Medical Center</ethicname>
      <ethicaddress />
      <ethicapprovaldate>26/11/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Israel</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Tom Baker Cancer Centre</ethicname>
      <ethicaddress />
      <ethicapprovaldate>30/11/2005</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Canada</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Universitair Medisch Centrum Groningen</ethicname>
      <ethicaddress />
      <ethicapprovaldate>8/03/2005</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Netherlands</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>University of Cincinnati</ethicname>
      <ethicaddress />
      <ethicapprovaldate>29/09/2004</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>United States of America</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>University of Louisville</ethicname>
      <ethicaddress />
      <ethicapprovaldate>2/12/2005</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>United States of America</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>University of Texas Southwestern</ethicname>
      <ethicaddress />
      <ethicapprovaldate>8/11/2005</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>United States of America</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>University of Wurzburg</ethicname>
      <ethicaddress />
      <ethicapprovaldate>8/05/2006</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Germany</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Vanderbilt University</ethicname>
      <ethicaddress />
      <ethicapprovaldate>1/03/2006</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>United States of America</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Wake Forest University</ethicname>
      <ethicaddress />
      <ethicapprovaldate>7/12/2005</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>United States of America</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Westmead Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate>30/08/2005</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr. Donald L. Morton</name>
      <address>John Wayne Cancer Institute
2200 Santa Monica Blvd.
Santa Monica CA 90404</address>
      <phone>+1 310 829 8781</phone>
      <fax />
      <email>mortond@jwci.org</email>
      <country>United States of America</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Lisa van Kreuningen</name>
      <address>John Wayne Cancer Institute
2200 Santa Monica Blvd
Santa Monica CA 90404</address>
      <phone>+1 310 582 7053</phone>
      <fax>+1 310 998 3996</fax>
      <email>lvk@jwci.org</email>
      <country>United States of America</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Lisa van Kreuningen</name>
      <address>2200 Santa Monica Blvd.
Santa Monica, CA 90404</address>
      <phone>1-310-582-7053</phone>
      <fax>1-310-998-3996</fax>
      <email>lvk@jwci.org</email>
      <country>United States of America</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>